《Adefovir dipivoxil for the treatment of chronic hepatitis B clinical observation（阿德福伟治疗慢性乙型肝炎的临床观察）》由会员分享，可在线阅读，更多相关《Adefovir dipivoxil for the treatment of chronic hepatitis B clinical observation（阿德福伟治疗慢性乙型肝炎的临床观察）（8页珍藏版）》请在金锄头文库上搜索。
1、1Adefovir dipivoxil for the treatment of chronic hepatitis B clinical observationAbstract: Objective: To investigate adefovir dipivoxil clinical efficacy and adverse effects of treatment of chronic hepatitis B. Methods: Select from June 2010 to June 2011 chronic hepatitis B patients admitted to our
2、hospital, 98 cases, were randomly divided 49 cases for each of the observation group and the control group, the control group of patients given bicyclol 100 mg / d, ursodeoxycholic acid 250 mg / d, one day, once every six months, to observe patients in the control group treatment given on the basis
3、of adefovir dipivoxil 10 mg / d, twice a day, once every 6 months after the end of treatment, the clinical efficacy of the two groups were compared, the observed improvement in liver function indicators and adverse drug reaction. Results: The treatment after the end of the observation group, the tot
4、al effective rate was 90.77%, significantly higher than 72.31%, the difference was statistically significant ( 2 = 5.796, P 0.05. observation group, alanine aminotransferase (ALT, aspartate aminotransferase (AST, 2serum albumin (ALB, serum total bilirubin (TBiL recovery conditions are better than th
5、e control group, the differences were statistically significant (P 0.05. Conclusion: Adefovir dipivoxil treatment of chronic hepatitis B patients with significant liver function recovery, no significant adverse reactions occurred worthy of clinical promote the use of. Keywords: chronic hepatitis B,
6、adefovir dipivoxil, clinical efficacy Hepatitis B is one of the major diseases threatening the global human health has been reported that the 5-year survival rate of only 14% 1 this article the author used the co-administration of adefovir dipivoxil treatment of chronic hepatitis B, and achieved sat
7、isfactory effect, are reported as follows: 1 Materials and Methods 1.1 General Information Select from June 2010 to June 2011, 98 cases of chronic hepatitis B patients admitted to our hospital, are in line with the Chinese Medical Association in 2005 Hepatology 3and Infectious Diseases, credits will
8、 be jointly chronic hepatitis B prevention and treatment guidelines revised diagnostic criteria 2 , were randomly divided into observation group and control group 49 cases, 49 patients in the observation group, 38 men and 11 women, aged 27 to 68 years, an average of (49.37 + -2.98 years of age, the
9、control group of 49 patients , 36 males and 13 females, aged 26 to 69 years (mean 50.36 + -2.15 years old, two groups of gender, age, and general data showed no significant difference (P 0.05, comparable. 1.2 Methods Control group were treated with 100 mg / d of bicyclol, twice a day, ursodeoxycholi
10、c acid 250 mg / d, twice a day, once every six months. Observation group were given on the basis of the treatment in the control group A Defu Wei ester 10 mg / d, twice a day, once every six months after the end of treatment, the clinical efficacy of the two groups were compared, observed improvemen
11、t of liver function parameters and adverse drug reactions. liver function indicators including alanine aminotransferase (ALT, aspartate amino transferase (AST, serum albumin (of ALB, 4total serum bilirubin (TBiL. 1.3 Clinical evaluation standard markedly: the performance of liver function and resume
12、 normal ALT indicators. Effective: the performance of liver function, ALT indicator has been restored. Invalid: clinical manifestations improved serological examination showed no recovery. Total valid = markedly +. 1.4 statistical methods Using SPSS 13.0 statistical software processing data, count d
13、ata were compared using the chi-square test, measurement data were compared with the t test, data with the mean + - standard deviation (x +-s, said the difference was statistically significant at P 0.05. Links to free papers Download Center http:/2 results 2.1 Comparison of clinical efficacy end of
14、treatment, the observation group, the total effective rate was 90.77%, significantly higher than 72.31%, the difference was statistically significant (2 = 5.796, P 0.05. Shown 5in Table 1. Table 1 clinical efficacy n (% Note: Compared with the control group, * P 0.05 2.2 compare two groups of liver
15、function indicators After the end of treatment, the observation group, alanine aminotransferase (ALT, aspartate amino transferase (AST, serum albumin (of ALB, serum total bilirubin (TBiL recovery conditions are better than the control group, the differences were statistical significance (P 0.05, Table 2. Table 2 treatment after liver function indicators compare (x +-s 2.3 Adverse reactions After the end of treatment, the two groups were not liver, kidney function deterioration and other adverse reactions, clinical symptoms and signs were improve
